Celeste M. Boesjes

464 total citations
17 papers, 185 citations indexed

About

Celeste M. Boesjes is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Celeste M. Boesjes has authored 17 papers receiving a total of 185 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Dermatology, 13 papers in Immunology and Allergy and 10 papers in Physiology. Recurrent topics in Celeste M. Boesjes's work include Dermatology and Skin Diseases (16 papers), Allergic Rhinitis and Sensitization (13 papers) and Asthma and respiratory diseases (10 papers). Celeste M. Boesjes is often cited by papers focused on Dermatology and Skin Diseases (16 papers), Allergic Rhinitis and Sensitization (13 papers) and Asthma and respiratory diseases (10 papers). Celeste M. Boesjes collaborates with scholars based in Netherlands, Germany and United States. Celeste M. Boesjes's co-authors include Marjolein de Bruin‐Weller, Marlies de Graaf, Daphne S. Bakker, Lotte S. Spekhorst, Marie L. A. Schuttelaar, Laura Loman, Marijke Kamsteeg, Nicolaas P. A. Zuithoff, Inge Haeck and Geertruida L. E. Romeijn and has published in prestigious journals such as British Journal of Dermatology, Allergy and Clinical & Experimental Allergy.

In The Last Decade

Celeste M. Boesjes

17 papers receiving 184 citations

Peers

Countries citing papers authored by Celeste M. Boesjes

Since Specialization

Citations

This map shows the geographic impact of Celeste M. Boesjes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celeste M. Boesjes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celeste M. Boesjes more than expected).

Fields of papers citing papers by Celeste M. Boesjes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Celeste M. Boesjes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celeste M. Boesjes. The network helps show where Celeste M. Boesjes may publish in the future.

Co-authorship network of co-authors of Celeste M. Boesjes

This figure shows the co-authorship network connecting the top 25 collaborators of Celeste M. Boesjes. A scholar is included among the top collaborators of Celeste M. Boesjes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Celeste M. Boesjes. Celeste M. Boesjes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions 2025 ·Allergy ·Marjolein de Bruin‐Weller, Celeste M. Boesjes, (unknown), Lisa A. Beck, Alan D. Irvine, Christian Vestergaard, Marlies de Graaf, Femke van Wijk, Daphne S. Bakker, Stephan Weidinger	1
2	Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment 2025 ·Clinical & Experimental Allergy ·Celeste M. Boesjes, (unknown), Daphne S. Bakker, Constance F. den Hartog Jager, Marlies de Graaf, Marjolein de Bruin‐Weller, Femke van Wijk, Edward F. Knol	1
3	Single-cell sequencing of human Langerhans cells identifies altered gene expression profiles in patients with atopic dermatitis 2025 ·ImmunoHorizons ·(unknown), Marlot van der Wal, (unknown), (unknown), Celeste M. Boesjes, (unknown), Yvonne Pannekoek, Marrie C.A. Bruin, Femke van Wijk, Nina M. van Sorge	2
4	Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how? 2025 ·Journal of the European Academy of Dermatology and Venereology ·M. E. Jacobson, Celeste M. Boesjes, Marjolein de Bruin‐Weller, Marlies de Graaf, Ryota Morimoto, Eric L. Simpson	3
5	Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry 2024 ·Acta Dermato Venereologica ·(unknown), Celeste M. Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck, (unknown), Klaziena Politiek, (unknown), Marlies de Graaf, Marjolein de Bruin‐Weller, Marie L. A. Schuttelaar	16
6	Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial) 2023 ·British Journal of Dermatology ·(unknown), Renske Schappin, Marlies de Graaf, Ron A. Tupker, Karin B. Fieten, (unknown), Madelon B. Bronner, Geertruida L. E. Romeijn, (unknown), Celeste M. Boesjes, (unknown), B.W.M. Arents, Thomas Rustemeyer, Marie L. A. Schuttelaar, Suzanne G.M.A. Pasmans	2
7	Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry 2023 ·Acta Dermato Venereologica ·Celeste M. Boesjes, (unknown), Nicolaas P. A. Zuithoff, Daphne S. Bakker, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, Marlies de Graaf, Marjolein de Bruin‐Weller	16
8	Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry 2023 ·British Journal of Dermatology ·Lotte S. Spekhorst, Celeste M. Boesjes, Laura Loman, Nicolaas P. A. Zuithoff, Daphne S. Bakker, (unknown), Marijke Kamsteeg, Inge Haeck, Albert J. Oosting, P.P.M. van Lümig, (unknown), Ron A. Tupker, Annebeth Flinterman, F.M. Garritsen, (unknown), Marjolein de Bruin‐Weller, Marie L. A. Schuttelaar, Marlies de Graaf	20
9	Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation 2023 ·Clinical & Experimental Allergy ·Celeste M. Boesjes, Daphne S. Bakker, Edward F. Knol, Marlies de Graaf, Femke van Wijk, Marjolein de Bruin‐Weller	6
10	Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis 2023 ·JAMA Dermatology ·Celeste M. Boesjes, (unknown), Daphne S. Bakker, (unknown), Lotte S. Spekhorst, Marlies de Graaf, Marijke R. van Dijk, Marjolein de Bruin‐Weller	17
11	Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis 2022 ·Allergy ·Lotte S. Spekhorst, Daphne S. Bakker, Julia Drylewicz, Theo Rispens, Floris C. Loeff, Celeste M. Boesjes, Judith L. Thijs, Geertruida L. E. Romeijn, Laura Loman, Marie L. A. Schuttelaar, Femke van Wijk, Marlies de Graaf, Marjolein de Bruin‐Weller	31
12	Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry 2022 ·Acta Dermato Venereologica ·Celeste M. Boesjes, (unknown), Nicolaas P. A. Zuithoff, Daphne S. Bakker, Laura Loman, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, (unknown), F.M. Garritsen, Klaziena Politiek, J Oldhoff, Marlies de Graaf, Marie L. A. Schuttelaar, Marjolein de Bruin‐Weller	12
13	Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis 2022 ·JAMA Dermatology ·Lotte S. Spekhorst, Marlies de Graaf, Floris C. Loeff, Nicolaas P. A. Zuithoff, Daphne S. Bakker, Celeste M. Boesjes, Judith L. Thijs, (unknown), Femke van Wijk, Theo Rispens, Marjolein de Bruin‐Weller	10
14	Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry 2022 ·Pediatric Allergy and Immunology ·(unknown), Celeste M. Boesjes, Laura Loman, Daphne S. Bakker, (unknown), Nicolaas P. A. Zuithoff, Marijke Kamsteeg, Geertruida L. E. Romeijn, Femke van Wijk, Marjolein de Bruin‐Weller, Marlies de Graaf, Marie L. A. Schuttelaar	17
15	Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis 2022 ·JAMA Dermatology ·Lotte S. Spekhorst, Marlies de Graaf, Nicolaas P. A. Zuithoff, J.M.P.A. van den Reek, Marijke Kamsteeg, Celeste M. Boesjes, Geertruida L. E. Romeijn, Laura Loman, Inge Haeck, Albert J. Oosting, (unknown), (unknown), Annebeth Flinterman, (unknown), (unknown), Marjolein de Bruin‐Weller, Marie L. A. Schuttelaar	20
16	Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry 2021 ·Journal of Dermatological Treatment ·Jart A. F. Oosterhaven, Lotte S. Spekhorst, (unknown), Angelique N. Voorberg, Geertruida L. E. Romeijn, Celeste M. Boesjes, Marlies de Graaf, Marjolein de Bruin‐Weller, Marie L. A. Schuttelaar	10
17	Posttraumatic unilateral perniosis: A case report 2019 ·JAAD Case Reports ·Celeste M. Boesjes, Bram D. van Rhijn, Marijke R. van Dijk, V. Sigurdsson	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact